These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 32209814)

  • 21. [New Potential Therapies for Chronic Hepatitis B].
    Yoo SH; Kwon JH
    Korean J Gastroenterol; 2019 Nov; 74(5):267-273. PubMed ID: 31765555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of hepatitis B virus reactivation with direct-acting antivirals against hepatitis C virus: A cohort study from Egypt and meta-analysis of published data.
    El Kassas M; Shimakawa Y; Ali-Eldin Z; Funk AL; Wifi MN; Zaky S; El-Raey F; Esmat G; Fontanet A
    Liver Int; 2018 Dec; 38(12):2159-2169. PubMed ID: 29738637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation.
    Fontaine H; Alric L; Labreuche J; Legendre B; Louvet A; Antoine C; Legendre CM; Hazzan M; Kamar N; Dharancy S; Pol S; Duhamel A; Mathurin P
    J Hepatol; 2019 May; 70(5):831-838. PubMed ID: 30879789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort.
    Mücke VT; Mücke MM; Peiffer KH; Weiler N; Welzel TM; Sarrazin C; Zeuzem S; Berger A; Vermehren J
    Aliment Pharmacol Ther; 2017 Aug; 46(4):432-439. PubMed ID: 28627791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New antivirals for the treatment of chronic hepatitis B.
    Soriano V; Barreiro P; Benitez L; Peña JM; de Mendoza C
    Expert Opin Investig Drugs; 2017 Jul; 26(7):843-851. PubMed ID: 28521532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
    Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
    J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody-mediated immunotherapy against chronic hepatitis B virus infection.
    Gao Y; Zhang TY; Yuan Q; Xia NS
    Hum Vaccin Immunother; 2017 Aug; 13(8):1768-1773. PubMed ID: 28521640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel orally available small molecule that inhibits hepatitis B virus expression.
    Mueller H; Wildum S; Luangsay S; Walther J; Lopez A; Tropberger P; Ottaviani G; Lu W; Parrott NJ; Zhang JD; Schmucki R; Racek T; Hoflack JC; Kueng E; Point F; Zhou X; Steiner G; Lütgehetmann M; Rapp G; Volz T; Dandri M; Yang S; Young JAT; Javanbakht H
    J Hepatol; 2018 Mar; 68(3):412-420. PubMed ID: 29079285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New viral biomarkers for Hepatitis B: Are we able to change practice?
    Höner Zu Siederdissen C; Maasoumy B; Cornberg M
    J Viral Hepat; 2018 Nov; 25(11):1226-1235. PubMed ID: 30187603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New treatments to reach functional cure: Virological approaches.
    Durantel D
    Best Pract Res Clin Gastroenterol; 2017 Jun; 31(3):329-336. PubMed ID: 28774415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HBsAg, Subviral Particles, and Their Clearance in Establishing a Functional Cure of Chronic Hepatitis B Virus Infection.
    Vaillant A
    ACS Infect Dis; 2021 Jun; 7(6):1351-1368. PubMed ID: 33302622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs.
    Lu F; Wang J; Chen X; Xu D; Xia N
    Front Med; 2017 Dec; 11(4):502-508. PubMed ID: 29170915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.
    Calvaruso V; Ferraro D; Licata A; Bavetta MG; Petta S; Bronte F; Colomba G; Craxì A; Di Marco V
    J Viral Hepat; 2018 Jan; 25(1):72-79. PubMed ID: 28703895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
    Sagnelli E; Pisaturo M; Martini S; Sagnelli C; Filippini P; Coppola N
    Expert Opin Pharmacother; 2014 Jul; 15(10):1337-49. PubMed ID: 24773464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?
    Alonso S; Guerra AR; Carreira L; Ferrer JÁ; Gutiérrez ML; Fernandez-Rodriguez CM
    BMC Gastroenterol; 2017 Dec; 17(1):168. PubMed ID: 29268704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
    Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
    Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
    Buster EH; Schalm SW; Janssen HL
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibiting the Secretion of Hepatitis B Surface Antigen (HBsAg) to Treat Hepatitis B Infection- a Review.
    Baugh SDP
    Infect Disord Drug Targets; 2017; 17(1):24-35. PubMed ID: 28056752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent Drug Development in the Woodchuck Model of Chronic Hepatitis B.
    Suresh M; Menne S
    Viruses; 2022 Aug; 14(8):. PubMed ID: 36016334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.